Gossamer Bio (GOSS) Stock Price

Gossamer Bio Price

NASDAQ·CLOSED
0.17USD-0.0080 (-4.60 %)
Market closed

For Gossamer Bio, the net margin of -351.5% is down versus -49.3% a few years ago. The consensus 12-month price target for Gossamer Bio is 2.04 USD, about 1,100.0% above where the stock trades today. Of 15 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 21% above its 52-week low.

Gossamer Bio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Gossamer Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Gossamer Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Gossamer Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Gossamer Bio Stock Price History
DateGossamer Bio Price
7/31/20260.17 USD
7/30/20260.18 USD
7/29/20260.20 USD
7/27/20260.19 USD
7/23/20260.14 USD
7/22/20260.14 USD
7/21/20260.16 USD
7/20/20260.14 USD
7/17/20260.17 USD
7/16/20260.17 USD
7/15/20260.16 USD
7/14/20260.14 USD
7/13/20260.15 USD
7/10/20260.17 USD
7/9/20260.17 USD
7/8/20260.17 USD
7/7/20260.18 USD
7/6/20260.17 USD
7/2/20260.17 USD
7/1/20260.17 USD
6/30/20260.16 USD
6/29/20260.16 USD
6/26/20260.16 USD
6/25/20260.17 USD
6/24/20260.17 USD
6/23/20260.17 USD
6/22/20260.17 USD
6/18/20260.17 USD
6/17/20260.18 USD
6/16/20260.17 USD
6/15/20260.17 USD
6/12/20260.16 USD
6/11/20260.18 USD
6/10/20260.16 USD
6/9/20260.16 USD
6/8/20260.17 USD
6/5/20260.17 USD
6/4/20260.18 USD
6/3/20260.19 USD
6/2/20260.20 USD
6/1/20260.20 USD
5/29/20260.23 USD
5/28/20260.21 USD
5/27/20260.22 USD
5/26/20260.22 USD
5/22/20260.21 USD
5/21/20260.20 USD
5/20/20260.22 USD
5/19/20260.20 USD
5/18/20260.19 USD
5/15/20260.19 USD
5/14/20260.19 USD
5/13/20260.20 USD
5/12/20260.19 USD
5/11/20260.19 USD
5/8/20260.19 USD
5/7/20260.20 USD
5/6/20260.20 USD
5/5/20260.19 USD
5/4/20260.20 USD
5/1/20260.21 USD
4/30/20260.21 USD
4/29/20260.20 USD
4/28/20260.20 USD
4/27/20260.20 USD
4/24/20260.21 USD
4/23/20260.21 USD
4/22/20260.22 USD
4/21/20260.21 USD
4/20/20260.24 USD
4/17/20260.25 USD
4/16/20260.25 USD
4/15/20260.26 USD
4/14/20260.25 USD
4/13/20260.23 USD
4/10/20260.23 USD
4/9/20260.21 USD
4/8/20260.20 USD
4/7/20260.19 USD
4/6/20260.20 USD
4/2/20260.21 USD
4/1/20260.21 USD
3/31/20260.19 USD
3/30/20260.18 USD
3/27/20260.20 USD
3/26/20260.21 USD
3/25/20260.22 USD
3/24/20260.20 USD
3/23/20260.21 USD
3/20/20260.24 USD
3/19/20260.26 USD
3/18/20260.25 USD
3/17/20260.27 USD
3/16/20260.26 USD
3/13/20260.25 USD
3/12/20260.26 USD
3/11/20260.28 USD
3/10/20260.29 USD
3/9/20260.32 USD
3/6/20260.28 USD
3/5/20260.30 USD
3/4/20260.33 USD
3/3/20260.27 USD
3/2/20260.24 USD
2/27/20260.24 USD
2/26/20260.23 USD
2/25/20260.22 USD
2/24/20260.24 USD
2/23/20260.24 USD
2/20/20260.24 USD
2/19/20260.24 USD
2/18/20260.24 USD
2/17/20260.24 USD
2/13/20260.26 USD
2/12/20260.26 USD
2/11/20260.26 USD
2/10/20260.26 USD
2/9/20260.25 USD
2/6/20260.25 USD
2/5/20260.27 USD
2/4/20260.28 USD
2/3/20260.30 USD
2/2/20260.28 USD
1/30/20260.26 USD
1/29/20260.27 USD
1/28/20260.29 USD
1/27/20260.30 USD
1/26/20260.30 USD
1/23/20260.30 USD
1/22/20260.32 USD
1/21/20260.31 USD
1/20/20260.29 USD
1/16/20260.28 USD
1/15/20260.28 USD
1/14/20260.29 USD
1/13/20260.30 USD
1/12/20260.28 USD
1/9/20260.28 USD
1/8/20260.28 USD
1/7/20260.27 USD
1/6/20260.29 USD
1/5/20260.31 USD
1/2/20260.32 USD
12/31/20250.35 USD
12/30/20250.35 USD
12/29/20250.36 USD
12/26/20250.36 USD
12/24/20250.39 USD
12/23/20250.37 USD
12/22/20250.42 USD
12/19/20250.39 USD
12/18/20250.39 USD
12/17/20250.40 USD
12/16/20250.40 USD
12/15/20250.43 USD
12/12/20250.41 USD
12/11/20250.41 USD
12/10/20250.39 USD
12/9/20250.39 USD
12/8/20250.38 USD
12/5/20250.38 USD
12/4/20250.37 USD
12/3/20250.39 USD
12/2/20250.34 USD
12/1/20250.35 USD
11/28/20250.38 USD
11/26/20250.38 USD
11/25/20250.37 USD
11/24/20250.36 USD
11/21/20250.34 USD
11/20/20250.35 USD
11/19/20250.35 USD
11/18/20250.34 USD
11/17/20250.34 USD
11/14/20250.31 USD
11/13/20250.28 USD
11/12/20250.30 USD
11/11/20250.29 USD
11/10/20250.28 USD
11/7/20250.27 USD
11/6/20250.26 USD
11/5/20250.27 USD
11/4/20250.26 USD
11/3/20250.27 USD
10/31/20250.28 USD
10/30/20250.27 USD
10/29/20250.27 USD
10/28/20250.27 USD
10/27/20250.27 USD
10/24/20250.28 USD
10/23/20250.24 USD
10/22/20250.25 USD
10/21/20250.25 USD
10/20/20250.26 USD
10/17/20250.25 USD
10/16/20250.26 USD
10/15/20250.27 USD
10/14/20250.27 USD
10/13/20250.28 USD
10/10/20250.26 USD
10/9/20250.29 USD
10/8/20250.27 USD
10/7/20250.28 USD
10/6/20250.27 USD
10/3/20250.29 USD
10/2/20250.28 USD
10/1/20250.28 USD
9/30/20250.30 USD
9/29/20250.32 USD
9/26/20250.30 USD
9/25/20250.31 USD
9/24/20250.34 USD
9/23/20250.35 USD
9/22/20250.36 USD
9/19/20250.34 USD
9/18/20250.35 USD
9/17/20250.34 USD
9/16/20250.36 USD
9/15/20250.36 USD
9/12/20250.39 USD
9/11/20250.39 USD
9/10/20250.35 USD
9/9/20250.31 USD
9/8/20250.30 USD
9/5/20250.33 USD
9/4/20250.28 USD
9/3/20250.29 USD
9/2/20250.29 USD
8/29/20250.28 USD
8/28/20250.27 USD
8/27/20250.28 USD
8/26/20250.29 USD
8/25/20250.27 USD
8/22/20250.26 USD
8/21/20250.24 USD
8/20/20250.22 USD
8/19/20250.22 USD
8/18/20250.22 USD
8/15/20250.22 USD
8/14/20250.22 USD
8/13/20250.22 USD
8/12/20250.22 USD
8/11/20250.20 USD
8/8/20250.20 USD
8/7/20250.20 USD
8/6/20250.22 USD
8/5/20250.24 USD
8/4/20250.24 USD
Access this data via the Eulerpool API
Get Free API Key

Gossamer Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-183.76 M USD
-179.82 M USD
Jan 1, 2024
114.70 M USD
-59.92 M USD
-56.53 M USD
Jan 1, 2025
48.47 M USD
-161.44 M USD
-170.37 M USD
Jan 1, 2026 (e)
36.44 M USD
11.77 M USD
-90.49 M USD
Jan 1, 2027 (e)
53.00 M USD
17.12 M USD
-21.09 M USD
Jan 1, 2028 (e)
132.40 M USD
42.77 M USD
11.43 M USD
Jan 1, 2029 (e)
241.56 M USD
78.04 M USD
40.22 M USD
Jan 1, 2030 (e)
353.27 M USD
114.13 M USD
49.36 M USD

Gossamer Bio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 1:06 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e
––––––––114.0048.0036.0052.00132.00241.00353.00
–––––––––-57.89-25.0044.44153.8582.5846.47
––––––––100.0097.9297.9297.9297.9297.9297.92
47.0047.0047.00-3.00-4.00-5.00-4.00-4.00114.0047.0035.2550.92129.25235.98345.65
–-6.00-148.00-186.00-230.00-215.00-217.00-183.00-59.00-161.0011.0017.0042.0078.00114.00
––––––––-51.75-335.4230.5632.6931.8232.3732.29
–-6.00-146.00-180.00-243.00-234.00-229.00-179.00-56.00-170.00-90.00-21.0011.0040.0049.00
––2,333.3323.2935.00-3.70-2.14-21.83-68.72203.57-47.06-76.67-152.38263.6422.50
226.6024.8324.8361.2873.2175.5994.28225.41226.60226.60226.60226.60226.60226.60226.60
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Gossamer Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Gossamer Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Gossamer Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Gossamer Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Gossamer Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Gossamer Bio stock margins

The Gossamer Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gossamer Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gossamer Bio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
97.93 %
- %
- %
Jan 1, 2022
97.93 %
- %
- %
Jan 1, 2023
97.93 %
- %
- %
Jan 1, 2024
100.00 %
-52.24 %
-49.28 %
Jan 1, 2025
97.93 %
-333.06 %
-351.49 %
Jan 1, 2026 (e)
97.93 %
32.31 %
-248.36 %
Jan 1, 2027 (e)
97.93 %
32.31 %
-39.79 %
Jan 1, 2028 (e)
97.93 %
32.31 %
8.63 %

Gossamer Bio Stock Revenue, EBIT, Earnings per Share

The Gossamer Bio earnings per share therefore indicates how much revenue Gossamer Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-2.85 USD
-3.10 USD
Jan 1, 2022
0.00 USD
-2.30 USD
-2.43 USD
Jan 1, 2023
0.00 USD
-0.82 USD
-0.80 USD
Jan 1, 2024
0.51 USD
-0.26 USD
-0.25 USD
Jan 1, 2025
0.21 USD
-0.71 USD
-0.75 USD
Jan 1, 2026 (e)
0.16 USD
0.05 USD
-0.40 USD
Jan 1, 2027 (e)
0.23 USD
0.08 USD
-0.09 USD
Jan 1, 2028 (e)
0.58 USD
0.19 USD
0.05 USD

Gossamer Bio business model & stock analysis

The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide.

Gossamer Bio SWOT Analysis

Strengths

Gossamer Bio Inc has several strengths that give it a competitive advantage in the market. These include:

Gossamer Bio Inc boasts a diverse and innovative product portfolio that caters to various medical needs. This allows the company to target multiple market segments and increase its revenue potential.

The company is led by a highly skilled and experienced management team with a proven track record in the pharmaceutical industry. Their expertise contributes to effective decision-making and strategic planning.

Weaknesses

Despite its strengths, Gossamer Bio Inc also faces certain weaknesses that it needs to address in order to improve its market position:

Compared to some of its competitors, Gossamer Bio Inc has a relatively limited market presence. This can hinder its ability to reach a larger customer base and compete effectively in certain markets.

Developing and conducting extensive research for new medical products can be costly for Gossamer Bio Inc. This may put pressure on its financial resources and limit its ability to invest in other areas of the business.

Opportunities

Gossamer Bio Inc can leverage the following opportunities to expand its market share and achieve business growth:

Expanding into emerging markets presents an opportunity for Gossamer Bio Inc to tap into new customer bases and increase its revenue streams. These markets often have growing demand for healthcare products.

Rapid advancements in technology present opportunities for Gossamer Bio Inc to develop innovative solutions and improve existing products. This can enhance the company's competitiveness and attract more customers.

Threats

Gossamer Bio Inc should also be aware of potential threats in the market that could hinder its growth:

The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Gossamer Bio Inc must continually innovate and differentiate itself to stay ahead of competitors.

The pharmaceutical industry is subject to strict regulations and compliance requirements. Gossamer Bio Inc must ensure that its products meet all necessary regulations, which can be time-consuming and costly.

Gossamer Bio Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gossamer Bio Employees
Details
Date
Gossamer Bio Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Gossamer Bio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Gossamer Bio historical P/E ratio, EBIT multiple, and P/S ratio

Gossamer Bio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Gossamer Bio shares outstanding

The number of shares of Gossamer Bio was 226.6 M in 2025. This indicates how many shares Gossamer Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
75.59 M Stocks
Jan 1, 2022
94.28 M Stocks
Jan 1, 2023
225.41 M Stocks
Jan 1, 2024
226.60 M Stocks
Jan 1, 2025
226.60 M Stocks
Jan 1, 2026 (e)
226.60 M Stocks
Jan 1, 2027 (e)
226.60 M Stocks
Jan 1, 2028 (e)
226.60 M Stocks

Current Gossamer Bio forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
77.78 %
Buy
60.00 % (9)
Hold
33.33 % (5)
Sell
6.67 % (1)
12M Price Target
2.04
Last Price
0.17
Currency
USD
12M Return Potential
1,100.00 %
LTM Return
0 %

Gossamer Bio Analyst Rating Actions

DateFirmActionRatingReliability
7/28/2026
Leerink Partners
Leerink Partners
UpgradeMarket PerformOutperform–
7/27/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/25/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/26/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/19/2026
Barclays
Barclays
MaintainedUnderweight33
3/23/2026
Cantor Fitzgerald
Cantor Fitzgerald
DowngradeOverweightNeutral44
3/6/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/5/2026
Oppenheimer
Oppenheimer
MaintainedOutperform65
2/24/2026
Wedbush
Wedbush
DowngradeOutperformNeutral59
2/24/2026
Leerink Partners
Leerink Partners
DowngradeOutperformMarket Perform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Gossamer Bio Earnings Calls

Gossamer Bio Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-0.13USD-5.30 MUSD-2026 Q2
5/13/2026-0.17USD-5.39 MUSD-2026 Q1
3/13/2026-0.20USD-7.67 MUSD-2025 Q4
8/11/2025-0.18USD-4.43 MUSD-2025 Q2
11/12/2024-0.15USD-7.85 MUSD-2024 Q3
5/7/2024-0.20USD-0.00USD-2024 Q1
3/15/2024-0.21USD-0.00USD-2023 Q4
8/7/2023-0.63USD-0.00USD-2023 Q2
5/8/2023-0.61USD-0.00USD-2023 Q1
3/1/2023-0.63USD-0.00USD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Gossamer Bio stock

50/100
51
Environment
69
Social
29
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees55
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Gossamer Bio shareholder structure

% Name
6.32298%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
6.08937%
Octagon Capital Advisors LP
Octagon Capital Advisors LP
5.63332%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.07448%
State Street Investment Management (US)
State Street Investment Management (US)
3.52527%
ARCH Venture Partners
ARCH Venture Partners
3.50080%
683 Capital Management LLC
683 Capital Management LLC
...

Gossamer Bio Beneficial Ownership Filings (SEC 13D/G)

Free Float
76.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
29.47%
STATE STREET CORPORATION
STATE STREET CORPORATION
SEC ↗
28.17%
SSGA FUNDS MANAGEMENT, INC.
SSGA FUNDS MANAGEMENT, INC.
SEC ↗
12.20%
Robert Nelsen
Robert Nelsen
SEC ↗
12.20%
Keith Crandell
Keith Crandell
SEC ↗
12.20%
Clinton Bybee
Clinton Bybee
SEC ↗
12.20%
ARCH Venture Partners IX Overage, L.P.
ARCH Venture Partners IX Overage, L.P.
SEC ↗
12.20%
ARCH Venture Partners IX, L.P.
ARCH Venture Partners IX, L.P.
SEC ↗
9.99%
683 Capital Management, LLC
683 Capital Management, LLC
SEC ↗
9.90%
Context Capital Management, LLC
Context Capital Management, LLC
SEC ↗
9.30%
of 11 Pages
of 11 Pages
SEC ↗

Gossamer Bio Executives and Management Board

12 members · avg. age 60 · 25 % women

FH

Mr. Faheem Hasnain (66)

Chairman of the Board, President, Chief Executive Officer, Co-Founder · since 2018

2.01 M USD

Management

CW

Mr. Christian Waage (58)

Executive Vice President - Technical Operations and Administration

1.65 M USD
RS

Mr. Robert Smith (56)

Chief Commercial Officer

1.33 M USD
BG

Mr. Bryan Giraudo (50)

Chief Operating Officer, Chief Financial Officer

1.17 M USD
RA

Dr. Richard Aranda (65)

Chief Medical Officer

1.07 M USD
CP

Ms. Caryn Peterson (66)

Executive Vice President - Regulatory Affairs

–

Board of Directors

SD

Dr. Skye Drynan (49)

Independent Director

290,415.00 USD
SN

Dr. Steven Nathan (66)

Independent Director

284,915.00 USD
TD

Dr. Thomas Daniel (71)

Lead Independent Director

128,465.00 USD
RC

Mr. Russell Cox (62)

Independent Director

114,965.00 USD
SM

Dr. Sandra Milligan (61)

Independent Director

109,465.00 USD
JQ

Dr. John Quisel (53)

Independent Director

102,965.00 USD

Frequently asked questions about Gossamer Bio

The business model of Gossamer Bio Inc revolves around the development and commercialization of innovative therapeutics for patients with severe and life-threatening diseases. As an emerging biopharmaceutical company, Gossamer Bio focuses on discovering and advancing its pipeline of novel, differentiated drug candidates. With a commitment to scientific excellence and strategic partnerships, Gossamer Bio aims to address unmet medical needs by bringing transformative therapies to patients worldwide.

Gossamer Bio Inc is primarily active in the biotechnology industry.

The main competitors of Gossamer Bio Inc in the market are Amgen Inc, Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated.

Gossamer Bio Inc is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics to treat immune-related diseases. Founded in 2015, Gossamer Bio has swiftly emerged as a leader in the biotech industry. With a strong emphasis on innovative research and strategic partnerships, the company aims to address various unmet medical needs. Gossamer Bio's dedicated team of experts strives to enhance patients' lives by advancing the development of novel treatments. With a commitment to scientific excellence, Gossamer Bio Inc remains at the forefront of cutting-edge therapies to improve patient outcomes and revolutionize the field of immunology.

Gossamer Bio Inc has achieved several significant milestones in its journey. Firstly, the company successfully completed its initial public offering (IPO) in February 2019, raising substantial funds to support its operations and growth. Additionally, Gossamer Bio Inc has made significant progress in its clinical pipeline, with the initiation of Phase 2 studies for its lead product candidates in areas such as asthma, chronic rhinosinusitis, and inflammatory bowel disease. These milestones demonstrate the company's commitment to advancing innovative therapies that address unmet medical needs. Gossamer Bio Inc's ongoing efforts and achievements position it as a prominent player in the biopharmaceutical industry.

Gossamer Bio Inc is primarily present in the United States.

Gossamer Bio Inc represents values of innovation, collaboration, and dedication to improving patient outcomes. The company's corporate philosophy revolves around developing and advancing novel therapeutic solutions to address significant unmet medical needs. With a focus on precision medicine and leveraging cutting-edge technology, Gossamer Bio Inc aims to transform the lives of patients by developing innovative treatments for complex diseases. By prioritizing patient-centered approaches and fostering partnerships within the scientific and medical communities, Gossamer Bio Inc strives to make a meaningful impact on healthcare and drive positive change for patients worldwide.

Analysts currently set an average price target of 4.44 USD for the Gossamer Bio stock (median: 2.04 USD), implying +2,510.0 % versus the latest price. The consensus is based on 15 analyst ratings.

Gossamer Bio Analyst Price Targets 2026

16 analysts currently rate the Gossamer Bio stock: 10 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Gossamer Bio to generate revenue of 36.44 M USD and earnings per share of -0.40 USD.

Gossamer Bio Analyst Price Targets 2026

Converted at the current exchange rate, the Gossamer Bio share trades at 0.15 EUR (0.17 USD).

The Gossamer Bio share (GOSS) is listed on 4 stock exchanges, including: NASDAQ (GOSS), Frankfurt (4GB.F), München (4GB.MU), Düsseldorf (4GB.DU).

Gossamer Bio Inc is an American biotechnology company that is dedicated to the discovery and development of new therapeutics for specific diseases. The company was founded in 2018 by an experienced team of executives and experts in the biotechnology industry. Gossamer Bio is headquartered in San Diego, California and currently employs over 100 employees. The business model of Gossamer Bio can be divided into three main areas: research and development, clinical trials, and marketing. The research and development division focuses on identifying new drug candidates for diseases such as respiratory diseases, inflammatory diseases, oncology, and infectious diseases. The company utilizes state-of-the-art technologies and platforms to identify and optimize promising candidates before testing them in clinical trials. Clinical trials play a crucial role in evaluating the efficacy and safety of drug candidates. Gossamer Bio conducts carefully planned studies to achieve scientific validation of the therapeutics. The company also utilizes a network of leading clinical facilities and research centers to conduct studies and collect data. This helps the company evaluate the efficacy and safety of the therapeutics and submit the best recommendation for drug approval to regulatory authorities. Once the clinical trials are completed and the therapeutics are approved, the company moves into the marketing phase. Gossamer Bio offers its therapeutics directly to patients and healthcare professionals through distribution and marketing channels. The company also utilizes partnerships and licensing agreements to enhance access to various markets and regions. This helps the company minimize distribution costs and maximize the reach of its therapeutics. Gossamer Bio already has several promising drug candidates in its pipeline, including GB001, GB002, GB004, and GB1275. Most of them are targeted towards respiratory diseases such as asthma, chronic lung disease, and idiopathic pulmonary fibrosis. GB001 is an inhaled breast cancer medication, while GB1275 targets various solid tumors including pancreatic cancer. Overall, Gossamer Bio has a strong business model that focuses on research and development, clinical trials, and marketing. As an innovative biotechnology company, they are committed to developing groundbreaking therapeutics that can benefit patients worldwide. Through strategic partnerships and telemedicine models, Gossamer Bio is working to improve healthcare and insurance to ensure that everyone in the world has access to top-quality therapeutics to improve their health.

The expected revenue of Gossamer Bio is 36.44 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Gossamer Bio is -90.49 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Gossamer Bio is currently -0.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Gossamer Bio stock.

The price-to-sales ratio (P/S) of Gossamer Bio is currently 1.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Gossamer Bio stock.

The Eulerpool Quality Score for Gossamer Bio is 3/10.

The ISIN of Gossamer Bio is US38341P1021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Gossamer Bio is A2PCBS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Gossamer Bio is GOSS. The ticker symbol is used to trade Gossamer Bio shares on the stock exchange.

Gossamer Bio paid dividends every year for the past 0 years.

Gossamer Bio is assigned to the 'Health' sector.

The dividends of Gossamer Bio are distributed in USD.

All fundamentals and in-depth analysis of Gossamer Bio

Our stock analysis for Gossamer Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gossamer Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Gossamer Bio Stock
Gossamer Bio Revenue→
Gossamer Bio Stock
Gossamer Bio Net Income→
Gossamer Bio Stock
Gossamer Bio P/E→
Gossamer Bio Stock
Gossamer Bio P/S→
Gossamer Bio Stock
Gossamer Bio EBIT→
Gossamer Bio Stock
Gossamer Bio Dividend→
Gossamer Bio Stock
Gossamer Bio Directors Dealings→
Gossamer Bio Stock
Gossamer Bio Stocks→
Gossamer Bio Stock
Gossamer Bio Market capitalization→
Gossamer Bio Stock
Gossamer Bio Debt→
Gossamer Bio Stock
Gossamer Bio Liabilities→
Gossamer Bio Stock
Gossamer Bio Equity→
Gossamer Bio Stock
Gossamer Bio AAQS→
Gossamer Bio Stock
Gossamer Bio Employees→
Gossamer Bio Stock
Gossamer Bio ROE→
Gossamer Bio Stock
Gossamer Bio ROA→
Gossamer Bio Stock
Gossamer Bio ROCE→
Gossamer Bio Stock
Gossamer Bio News→
Gossamer Bio Stock
Gossamer Bio Analyst Price Targets→

Health Stocks

GPI SpAGoodwill E-Health Info CoGPT HealthcareGoodRx HoldingsGrace BreedingGood Fellow Healthcare HoldingsGrace Therapeutics,Gongwin Biopharm Holdings CograceNT AG in LiquidationGolden HouseGrailGodavari DrugsAll Stocks A–Z →